Stock Price, News, Quote and Profile of PRELUDE THERAPEUTICS INC(NASDAQ:PRLD) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (5/17/2024, 7:21:06 PM)

After market: 4 0 (0%)

-0.28 (-6.54%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap219.72M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 122 full-time employees. The company went IPO on 2020-09-25. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. The Company’s product candidates include PRT1419, PRT2527, PRT3789, and PRT3645. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is a potent and highly selective CDK9 inhibitor. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid tumor models with MYC. PRT3645 is a next-generation CDK4/6 inhibitor. PRT3789 is an IV-administered SMARCA2 degrader. Its pipeline consists of multiple distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders.

Company Info

PRELUDE THERAPEUTICS INC

175 Innovation Boulevard

Wilmington DELAWARE 19803

P: 13024671280

CEO: Krishna Vaddi

Employees: 122

Website: https://preludetx.com/

PRLD News

10 days ago - Prelude Therapeutics, Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...

12 days ago - InvestorPlacePRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024

PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

12 days ago - Prelude Therapeutics, Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data...

a month ago - Prelude Therapeutics, Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

PRELUDE THERAPEUTICS INC (PRLD)

Nasdaq Stock Screener

USA Stock Screener